Discover the groundbreaking research on the Mosaic Bioprosthesis, a third-generation stented porcine bioprosthetic valve, with its long-term clinical outcomes highlighted in the study 'AUG Long-term Outcomes of the Mosaic Bioprosthesis' published by The Society of Thoracic Surgeons in 2018. This innovative valve, introduced in 1994 and approved by the FDA in 2000, boasts features like annular valve structure, glutaraldehyde physiological tissue fixation, zero-pressure valve leaf, and α-amino acid anti-calcification treatment. The Mosaic bioprosthetic valve has been the subject of a prospective, non-randomized, multicenter trial involving 17 centers across Canada, Australia, New Zealand, and Europe, followed by a long-term study at 6 centers post-FDA approval. These early and mid-term studies demonstrate the Mosaic bioprosthetic valve's satisfactory clinical safety and efficacy. Create engaging and informative H5 presentations with the power of eqxiu.com's online design platform, featuring a rich library of templates for quick and easy creation.